AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 292 min read$TLRY

Tilray’s beverage business poised for volume growth as Carlsberg deal date nears, says Jefferies

Tilray (TLRY) is set to benefit from a partnership with Carlsberg, starting in 2027, which could increase its beverage volumes by 8% to 10%. Jefferies raised its price target to $13 from $12, citing improved capital returns and efficiency gains. Tilray aims for $20M in annual savings by 2028 and reaffirmed its FY2027 adjusted EBITDA guidance of $68M-$75M.

Original reporting
finance.yahoo.com
Published Oct 29, 2026, 6:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 6:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Tilray’s beverage business poised for volume growth as Carlsberg deal date nears, says Jefferies — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$TLRYBullishMed
01

Why it matters

The analyst upgrade reflects confidence in the partnership's ability to add 8‑10% volume and generate $20 M in annual cost savings.

02

Market read

New analyst target and partnership details provide fresh catalyst for Tilray's stock, suggesting near‑term upside.

03

What to watch

Potential inventory write‑downs or restructuring costs could offset anticipated savings.

Relevance 6/10Novelty 7/10Timing: today

Background

Tilray, primarily a cannabis producer, is expanding its beverage business through a partnership with Carlsberg to brew and distribute beer in the U.S.

Company-level read

Ticker impact

$TLRYBullishHigh confidence
Context

Jefferies raised Tilray's price target to $13, citing the upcoming Carlsberg partnership and expected volume boost.

Expected impact

likely upward pressure as the market prices in higher utilization and volume growth.

Evidence & confidence

The new target reflects expected incremental revenue and cost savings, which can attract buyers.

Market effects

Sector

May boost the cannabis‑linked beverage niche and signal further partnerships in the sector.

Regional

U.S. beverage market could see modest volume increase from Carlsberg products.

Global

Highlights cross‑industry collaborations between cannabis and mainstream alcohol brands.

Counterpoint

What could challenge this read

If volume growth falls short, the higher target may be premature and could lead to disappointment.

Key entities

  • company
    Tilray Inc

    US‑listed cannabis and beverage producer (NASDAQ:TLRY).

  • company
    Carlsberg

    Global brewer entering a partnership with Tilray.

Read at source← All news

Related articles

OCT 29
$TLRYMed

Jefferies raises Tilray stock price target on brewing restructuring

Jefferies raised its price target on Tilray Brands (TLRY) to $13 from $12, maintaining a Reduce rating. The stock trades at $2.67, down 80% over the past year. Tilray is restructuring its U.S. brewing operations, targeting $20 million in annual savings by 2028. The company reported $257.1 million in Q1 fiscal 2027 revenue, up 23% year-over-year, but posted a net loss of $40 million.

investing.com2 min
OCT 13
$TLRYMed

Tilray Medical Gains Approval For In-House Quality Testing At Portugal Facility

Tilray Brands (TLRY) received approval from Portugal's INFARMED for in-house quality testing at its Cantanhede facility. This allows microbiological and chemical/physical testing on-site, improving control and speeding up product release. The company expects reduced costs and faster supply to key markets like Germany and the UK. TLRY's stock closed at $3.36, down 5.08%, and was down 0.30% in premarket trading.

rttnews.com2 min
OCT 13
$TLRYMed

Tilray Brands, Inc.: Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets

Tilray Medical, a division of Tilray Brands (TLRY), received approval from Portugal's INFARMED to conduct in-house quality testing at its Cantanhede facility. This allows for faster product release and strengthens its global medical cannabis supply chain, benefiting markets like Germany and the UK. The move is expected to reduce costs and improve efficiency, supporting Tilray's position as a leading medical cannabis supplier.

finanznachrichten.de2 min
OCT 9
$TLRYLow

Should you sell your Tilray stock?

Tilray Brands (TSX:TLRY) reported fiscal Q1 2027 revenue of $257.1M and Adjusted EBITDA of $9.2M, missing analyst estimates. Cannabis revenue fell 13% year-over-year, while beverage alcohol revenue rose 82.1%. Analyst Neal Gilmer maintained a 'Hold' rating and $4.00 target, citing concerns about organic growth and cash flow.

cantechletter.com2 min